This study aimed to identify genetic mechanisms underlying severe retinal degeneration in one large family from northern Sweden, members of which presented with early-onset autosomal recessive retinitis pigmentosa and juvenile macular dystrophy. The clinical records of affected family members were analysed retrospectively and ophthalmological and electrophysiological examinations were performed in selected cases. Mutation screening was initially performed with microarrays, interrogating known mutations in the genes associated with recessive retinitis pigmentosa, Leber congenital amaurosis and Stargardt disease. Searching for homozygous regions with putative causative disease genes was done by high-density SNP-array genotyping, followed by segregation analysis of the family members. Two distinct phenotypes of retinal dystrophy, Leber congenital amaurosis and Stargardt disease were present in the family. In the family, four patients with Leber congenital amaurosis were homozygous for a novel c.2557C4T (p.Q853X) mutation in the CRB1 gene, while of two cases with Stargardt disease, one was homozygous for c.5461-10T4C in the ABCA4 gene and another was carrier of the same mutation and a novel ABCA4 mutation c.4773 þ 3A4G. Sequence analysis of the entire ABCA4 gene in patients with Stargardt disease revealed complex alleles with additional sequence variants, which were evaluated by bioinformatics tools. In conclusion, presence of different genetic mechanisms resulting in variable phenotype within the family is not rare and can challenge molecular geneticists, ophthalmologists and genetic counsellors.
INTRODUCTION
Leber congenital amaurosis (LCA) is a severe retinal dystrophy with onset of disease in early childhood. LCA is characterised by poor visual function, photophobia, high hyperopia, nystagmus, and severe retinal dysfunction. 1 The electroretinogram is usually undetectable or severely reduced. Mode of inheritance for LCA is typically autosomal recessive and diagnosis of disease is established by clinical findings, although molecular genetic testing is available for 15 genes. The following genes are known to be associated with LCA: GUCY2D, RPE65, SPATA7, AIPL1, LCA5, RPGRIP1, CRX, CRB1, CEP290, IMPDH1, RD3, RDH12, KCNJ13, LRAT and TULP1. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] It is difficult to estimate the proportion of patients with mutations in the different genes, as some, such as IMPDH1 (LCA11) is considered to be rare, other, as CEP290 accounts for almost 20%, and for some such as TULP1 and LRAT the number is uncertain. One of the most studied LCA genes is CRB1 at 1q31q32.1, which consists of 12 exons and encodes a protein Crumbs homologue that participates in determination and maintenance of photoreceptor architecture. Depending on the nature of the mutation, sequence changes in CRB1 can be disease causative in either LCA, retinitis pigmentosa (RP) 18 or RP with preserved para-arteriolar retinal pigment epithelium. 19 Stargardt disease (STGD1) is another autosomal recessive trait representing a severe form of retinal degeneration affecting the macula that begins in childhood. The gene responsible for STGD1 is ABCA4 at 1p22, which contains 50 exons and encodes a protein involved in energy transport to and from photoreceptor cells in the retina. Expressed exclusively in retinal photoreceptors, ABCA4 is involved in clearance of all-trans-retinal aldehyde that is a by-product of the retinoid cycle. 20 Clinical diagnosis of the disease is difficult during eye examinations in the first few years of onset when discrete yellow spots or atrophy are occasionally seen in the macula. So far, more than 600 ABCA4 mutations scattered throughout the coding sequence have been annotated. 21 In the same way as for the LCArelated genes, mutations in ABCA4 cause not only STGD1 but also cone-rod dystrophy and RP. 22, 23 Molecular genetic testing is desirable for facilitating the diagnosis of LCA, early-onset RP and STGD1. This study was conducted to investigate the genetic defects in a Swedish family that manifests two distinct retinal degenerations: STGD1 and LCA.
MATERIALS AND METHODS

Patients and Clinical Examination
DNA was available from 6 affected individuals and 10 unaffected relatives from a multigeneration family originating from Jämtland County in northern Sweden (Figure 1a ). In total, 356 control samples from a matched population were included in the study. Informed consent was obtained from all individuals participating in the study; the research followed the tenets of the Helsinki Declaration and was approved by the Ethics Committee of University of Umeå.
Clinical ophthalmological and electrophysiological examinations were performed and previous examination results of affected individuals along with their family history were collected from their home clinics. Full-field, singleflash, flicker electroretinograms and oscillatory potentials were recorded (UTAS-E 2000, LKC Technologies Inc., Gaithersburg, MD, USA) according to the recommendations of the International Society for Clinical Electrophysiology of Vision. 24 
Molecular genetic analysis
DNA from 16 individuals was extracted from peripheral blood lymphocytes using a previously described protocol. 25 Testing for the mutations reported as a cause of LCA, autosomal recessive RP and Stargardt disease was performed by arrayed primer extension (APEX) at AsperBiotech (Tartu, Estonia) (http:// www.asperbio.com/asper-ophthalmics). High-resolution genome-wide SNParray genotyping was applied for identification of homozygosity regions containing potential disease-causing genes. DNA was genotyped on a SNP microarray (Human610-Quad BeadChip, Illumina, San Diego, CA, USA) with 610 000 polymorphic SNPs according to manufacturer's instructions. The data were analysed using GenomeStudio software (Illumina). Genomic regions demonstrating homozygosity over 5 Mb were taken into account for further gene analysis.
For bi-directional sequencing of CRX1 (MIM 602225, NM_000554.4), CRB1 (MIM 604210, NM_201253.2) and ABCA4 (MIM 601691, NM_000350.2), coding exons and adjacent intronic sequences were amplified from genomic DNA. Primer pairs for CRX1 and CRB1 were designed with Primer3 software and are available upon request. PCR amplification and the sequencing reactions were performed as described elsewhere. 26 The products of sequencing reactions were analysed on ABI 3500xL Dx Genetic Analyser (Applied Biosystems, Foster City, CA, USA). Sequences were aligned and evaluated using the Sequencher software version 4.9 (Gene Codes Corporation, Ann Arbor, MI, USA). Sequencing of the entire coding region of ABCA4 was performed at AsperBiotech (http://www.asperbio.com/genetic-tests/panel-ofgenetic-tests/stargardt-disease-cone-rod-dystrophy-abca4).
All identified variants were denoted using accepted nomenclature recommended by Human Genome Variation Society. To predict the impact of sequence variants on the CRB1 and ABCA4 function, missense mutations were analysed by Sorting Intolerant from Tolerant (SIFT; http://sift.jcvi.org) and Polymorphism Phenotyping (PolyPhen; http://genetics.bwh.harvard.edu/pph). Variants detected in intronic sequences were analysed with the splice site prediction programs GeneSplicer (http://www.cbcb.umd.edu/software/GeneSplicer) and Splice Site Finder (www.genet.sickkids.on.ca/_ali/splicesitefinder). All bioinformatics tools were available via the Alamut software version 2.0 (Interactive Biosoftware, Rouen, France).
RESULTS
Clinical findings
In total, six affected patients with retinal degeneration were identified in a large Swedish family (Figure 1a The LCA cases showed severely reduced visual acuity or blindness in childhood, as well as nystagmus, convergent strabismus and severe The 472-bp-long PCR products amplified according to the conditions described in 'Materials and Methods' were digested with DdeI endonuclease and results were visualised on 2% agarose gel (SeaKem, ME Agarose, Lonza, Basel, Switzeland) by GelStar Nuclear Acid Staining (Cambrex, Bio Science Rockland Inc, Rockland, ME, USA). c.2557C4T mutation abolishes DdeI restriction site. LCA cases are indicated in red and STGD1 in blue.
hyperopia. In early childhood, the macular area showed central diffuse atrophy and the peripheral retina had an overall granulated appearance. In the late thirties, premature cataract evolved and synchysis scintillans were observed in the vitreous body in 2/4 LCA cases. In the central retina, areolar atrophy surrounded by prominent pigmentation of the macular area was found with generally dispersed pigmentary changes of more peripheral retina (Figure 2a) . No preservation of the para-arteriolar pigment epithelium or peripheral telangiectasia was observed in the LCA cases in adulthood. The fullfield electroretinogram responses described at the age of 3 years were extinguished in early childhood. The STGD1 cases demonstrated a different retinal phenotype. Visual acuity was affected at school age (8-14 years). Macular atrophy was present with some hyperpigmentation and yellowish flecks of the posterior pole with central visual field defects (Figures 2b and c) . The peripheral retina was preserved in young adulthood, although progressive retinal atrophy, peripheral retinal function and visual fields diminished in adulthood. No premature cataract was observed. In adulthood (VI:10, age 25 years), the recovery of standardised dark adaptation showed both cone and rod adaptation, with a final visual sensory threshold elevated by 1 log unit. In the full-field electroretinograms, the rod, mixed rod-cone and cone amplitudes were estimated within normal range but the 30-Hz flicker amplitude was decreased to 40% of normal level with prolonged implicit time.
Molecular genetic findings
Genetic testing for known mutations. DNA from two patients, one with LCA (VI:2) and another one with STGD1 (V:4), were analysed for the presence of previously reported sequence variants known as a cause or associated with autosomal recessive RP, LCA and STGD1. In total, 641 mutations in 13 LCA genes and 594 mutations in 19 RP genes on genotyping microarrays (commercially designed gene chips available via http://www.asperbio.com/asper-ophthalmics) were tested by APEX. In LCA patient VI:2, no mutations were identified by APEX analysis. This patient was heterozygous carrier of four SNPs, all predicted to be tolerated according to SIFT and PolyPhen (Table 1) . In STGD1 patient V:4, only one heterozygous variant c.5461-10T4C in the ABCA4 gene was detected, which was predicted to have a weak splice effect.
Homozygosity regions detection. Absence of detected mutations in the LCA patient, recessive inheritance pattern and presence of consanguinity loops in the family (Figure 1a ) encouraged us to undertake high-resolution SNP-array genotyping on both patients aiming to reveal regions of homozygosity containing potential disease-causing genes. In STGD1 patient V:4, only one 2.2 Mb homozygous region was identified that did not contain any known retinal genes and did not overlap with any of eight regions of homozygosity (ROH) detected in LCA individual VI:2 ( Table 2) . Two of the eight ROH on chromosomes 1 and 19 contained genes responsible for retinal degeneration. These genes, OPA3, causing autosomal recessive optic atrophy with chorea and spastic paraplegia, PRPF31, causing an autosomal dominant form of RP with reduced penetrance and CFH, increasing the likelihood of developing agerelated macular degeneration, were excluded as a potential cause of the disease in this family due to inheritance mode and absence of specific clinical appearance. Of the remaining candidate genes, the cone-rod homeobox gene (CRX1) on chromosome 19, known as a very rare cause of both dominant and recessive LCA, was less prioritised than the Crumbs homologue gene (CRB1) on chromosome 1, which was the most promising candidate gene responsible for the LCA phenotype in the family.
Sequence analysis of CRX1 and CRB1. Sequencing of the CRX1 in LCA patient VI:2 did not reveal any mutations and therefore this gene was excluded as a cause of the disease in the family. Sequencing of all 12 exons of CRB1 in the same patient identified a homozygous nonsense mutation c.2557C4T in exon 7, resulting in a premature stop codon and a truncated protein, p.Q853X (Figure 3a ). Segregation analysis of affected and unaffected members of the family was performed by restriction fragment length polymorphism analysis, using the DdeI endonuclease for digestion of CRB1 exon 7. The c.2557C4T (p.Q853X) mutation was present in homozygous form in all four LCA patients (Figure 1a and b, VI:2, VI:5, VI:6, VII:3), and in heterozygous form in the healthy parents of individual VII:3. It was absent in 356 control samples from a matched population. The c.2557C4T (p.Q853X) mutation has not been described in the literature previously and is thus novel to this Swedish family.
Sequence analysis of ABCA4. Sequence analysis of ABCA4 intron 38 in STGD1 patient V:4 confirmed heterozygosity of the mutation c.5461-10T4C detected in the APEX analysis (Figure 3b ). To determine if individual V:4 was a compound heterozygote, all exons and flanking intronic sequences of the ABCA4 were sequenced. In total, 12 sequence variants were detected, 8 of which were intronic and 4 exonic ( Table 3) . Of the intronic variants, the most interesting was a novel sequence variant in ABCA4 intron 33, c.4773 þ 3A4G (Figure 3c ), which was predicted to have a weak splice effect. Of the exonic variants, only p.N1868I and p.H423R were nonsynonymous. Bioinformatics analysis predicted p.N1868I to be possibly damaging for protein function, whereas p.H423R was predicted to be benign. Segregation analysis was done for three ABCA4 sequence variants, including p.N1868I, c.4773 þ 3A4G and c.5461-10T4C. The variant p.N1868I was found in homozygous form in STGD1 patient VI:10, and in heterozygous form in STGD1 patient V:4 and non-affected individuals V:6, V:7 and VI:8 (Figure 1a) . To determine if p.N1868I was a common variant in our population, we tested 115 control individuals from a matched geographic region and detected 16 heterozygous carriers. This yielded an estimated allele frequency of 0.139, which is higher than the reported allele frequency in the SNP database (MAF ¼ 0.029).
The novel variant c.4773 þ 3A4G was found in heterozygous form in the two LCA patients VI:2 and VI:5, in three unaffected individuals 
DISCUSSION
In this study, we approached patients with different clinical presentation belonging to the same multigeneration family of Swedish origin. Clinical diagnosis of LCA was recognised in four of six patients. CRB1 and ABCA4 mutations in the same family F Jonsson et al Molecular testing of LCA patients is quite laborious due to genetic heterogeneity involving 16 known LCA genes. Testing for known mutations by array technology provides fast and reliable results; however, it does not reveal novel mutations. Therefore, arrays interrogating disease-causing genes need to be updated along with the discovery of novel mutations. Despite some disadvantages, in many cases this method is used as a first-line screening to reveal genetic mechanisms underlying different ophthalmic disorders. In our study, however, none of the known LCA mutations was identified in the index patient with LCA (VI:2), and only one heterozygous mutation in the ABCA4 gene was found in the STGD1 patient (V:4).
Recently, it has been shown that genome-wide homozygosity mapping with SNP microarrays represents a powerful tool for mutation discovery in autosomal recessive disorders such as LCA and RP. [27] [28] [29] In one of these studies, identification of homozygosity regions and further sequencing of LCA genes within these regions resulted in detection of 10 homozygous mutations, 7 of which were novel. 27 LCA genes CEP290 and LCA5 were identified by the same approach. 7, 27 As inheritance pattern of the disease in our consanguineous family was autosomal recessive, we performed genome-wide genotyping in two affected patients, aiming at identification of homozygous regions. The LCA patient VI:2 demonstrated ROH of more than 5 Mb in size on six chromosomes, of which the most promising candidate gene was CRB1 on chromosome 1. Subsequent sequencing of CRB1 resulted in detection of a novel null mutation in exon 7, c.2557C4T (p.Q853X). Among 150 known CRB1 sequence variants, mutations in exon 7 are the most frequent (27%) and especially important for CRB1 function due to encoded laminin AG-like domain. 30, 31 The c.5461-10T4C mutation was first reported by Maugeri et al., 32 although its function is still not resolved. The functional consequence of c.5461-10T4C was accessed in a study with the Exon Trapping System by Rivera et al., 33 who classified this nucleotide change as a rare sequence variant, as only correctly spliced exon was detected. The majority of STGD1 patients are compound heterozygotes, with our patient V:4 not being an exception, representing one of multiple cases with the c.5461-10T4C mutation. The c.5461-10T4C variant was found to be the most prevalent allele among patients with autosomal recessive cone and cone-rod dystrophy (8 of 64 patients). 34 In another study, the variant was found in 27 of 518 STGD1 patients compared with 1 of 316 clinically matched control individuals. 33 It is to be noticed that another affected member (VI:10) in the same family was homozygous for the c.5461-10T4C mutation. None of our healthy controls carried the c.5461-10T4C mutation, in line with previous observations of different population carrier frequencies. 35 Interestingly, our STGD1 patients carried the sequence variant ABCA4 p.N1868I that was predicted to be possibly damaging, as well as acting as a risk-increasing factor in AMD. 36 In our study, this variant was detected in almost 14% of the healthy controls, which is higher compared with the maximal frequency of 7.5% reported in a Finnish population in the 1000 Genomes project. 36 It is worth mentioning that ABCA4 c.2588G4C (p.G863A), the most frequent autosomal recessive mutation in the European population, is disease causative only in combination with a severe ABCA4 mutation, 32 and does not result in a STGD1 phenotype when present bi-allelic or in combination with a mild ABCA4 mutation. Maugeri et al. 32 hypothesised the possibility of a carrier advantage due to the high carrier frequency of the 2588C allele in Sweden (1 out of 18), 37 although the incidence of STGD1 is not higher in our country than in the rest of Europe. The same phenomena can also be applied to p.N1868I.
In the heterozygous STGD1 patient (V:4), we discovered a novel sequence variant c.4773 þ 3A4G, which was predicted to reduce the strength of the donor splice site. While the manuscript was in preparation, this variant was also reported in one AMD patient. 36 This variant was not detected in 3510 controls of European American descent, 36 and in our study only one carrier of 113 tested was found. The effect of the c.4773 þ 3A4G mutation can be tested using RNA splicing analysis. However, when we performed RT-PCR analysis on RNA isolated from peripheral blood lymphocytes from the heterozygous patient VI:2, only correctly spliced exon was detected (data not shown). This result was not unexpected, as ABCA4 mRNA is expressed exclusively in retina. 38 In conclusion, we showed that in a large Swedish family, defects in two genes, CRB1 (c.2557C4T) and ABCA4 (c.5461-10T4C and c.4773 þ 3A4G), caused two different retinal diseases. This is a second report presenting data on the mutations affecting CRB1 and ABCA4 genes segregating with two different phenotypes, namely LCA and autosomal recessive retinitis pigmntosa in the same family. 39 Presence of different genetic mechanisms resulting in variable phenotype within the family probably is not such a rare event and should be considered in patient management and disease treatment.
